Rezolute, Inc.

Contributing Author

Recent Articles by Rezolute, Inc.

Oct-15	Rezolute to Participate in Upcoming Investor Conferences RZLT GlobeNewswire
Oct-09	Rezolute Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) RZLT GlobeNewswire
Sep-17	Rezolute Reports Fourth Quarter and Full Year Fiscal 2025 Financial Results and Provides Business Update RZLT GlobeNewswire
Sep-02	Rezolute Announces Alignment with FDA on Streamlined Design for Ongoing Phase 3 Trial of Ersodetug in Tumor Hyperinsulinism RZLT GlobeNewswire
Aug-27	Rezolute to Participate in Upcoming Investor Conferences RZLT GlobeNewswire
Aug-20	Rezolute Appoints Seasoned Commercial Executive Sunil Karnawat as Chief Commercial Officer RZLT GlobeNewswire
Jul-22	Rezolute to Participate in the BTIG Virtual Biotechnology Conference RZLT GlobeNewswire
Jul-09	Rezolute Announces Presentation of Participant Baseline Data from its Fully Enrolled Phase 3 Study of Ersodetug in Congenital Hyperinsulinism at the Upcoming Annual Meeting of the Endocrine Society (ENDO 2025) RZLT GlobeNewswire
May-28	Rezolute Announces Completion of Enrollment in the Phase 3 sunRIZE Study of Ersodetug in Patients with Congenital Hyperinsulinism RZLT GlobeNewswire
May-13	Rezolute Reports Third Quarter Fiscal 2025 Financial Results and Provides Business Update RZLT GlobeNewswire
May-05	Rezolute Receives Breakthrough Therapy Designation from FDA for Ersodetug in the Treatment of Hypoglycemia Due to Tumor Hyperinsulinism RZLT GlobeNewswire
May-01	Rezolute to Participate in Upcoming Investor Conferences RZLT GlobeNewswire